Pharmadrug Inc. (CSE:PHRX)
Canada · Delayed Price · Currency is CAD 0.0100
0.00 (0.00%)
Jun 18, 2026, 10:17 AM EST
Pharmadrug Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | - | - | 0.01 | |
Revenue Growth (YoY) | - | - | - | - | - | -98.98% |
Cost of Revenue | - | - | - | - | 0 | 0.01 |
Gross Profit | - | - | - | - | -0 | -0 |
Selling, General & Admin | 0.15 | 0.16 | 0.4 | 0.78 | 1.27 | 1.55 |
Research & Development | - | - | 0.14 | 0.23 | 0.71 | 0.55 |
Amortization of Goodwill & Intangibles | 0.05 | 0.05 | 0.05 | 0.03 | - | - |
Operating Expenses | 0.2 | 0.21 | 0.63 | 1.36 | 2.35 | 2.72 |
Operating Income | -0.2 | -0.21 | -0.63 | -1.36 | -2.36 | -2.72 |
Interest Expense | -0.35 | -0.31 | -0.2 | -0.33 | -0.22 | -0.06 |
Earnings From Equity Investments | -0.06 | - | - | - | - | - |
Currency Exchange Gain (Loss) | - | - | 0 | 0 | 0 | -0.73 |
Other Non Operating Income (Expenses) | -0.02 | -0.03 | -0.12 | -0.06 | -0.05 | -0.06 |
EBT Excluding Unusual Items | -0.63 | -0.55 | -0.95 | -1.76 | -2.62 | -3.57 |
Merger & Restructuring Charges | - | - | - | -1.43 | - | - |
Gain (Loss) on Sale of Investments | - | - | -0.01 | -0.05 | -0.61 | -0.72 |
Asset Writedown | - | - | - | -10.14 | - | - |
Legal Settlements | - | - | 0.13 | 0.07 | -0.07 | - |
Other Unusual Items | 0.12 | 0.12 | -0.04 | -0.96 | 0.05 | - |
Pretax Income | -0.51 | -0.43 | -0.87 | -14.27 | -3.25 | -4.28 |
Income Tax Expense | - | - | - | -1.01 | -0.19 | - |
Earnings From Continuing Operations | -0.51 | -0.43 | -0.87 | -13.26 | -3.06 | -4.28 |
Earnings From Discontinued Operations | - | - | - | - | -5.81 | -1.59 |
Net Income to Company | -0.51 | -0.43 | -0.87 | -13.26 | -8.88 | -5.87 |
Minority Interest in Earnings | 0.04 | 0.05 | 0.08 | 0.06 | - | 0.25 |
Net Income | -0.47 | -0.38 | -0.79 | -13.2 | -8.88 | -5.63 |
Net Income to Common | -0.47 | -0.38 | -0.79 | -13.2 | -8.88 | -5.63 |
Shares Outstanding (Basic) | 115 | 108 | 104 | 56 | 50 | 47 |
Shares Outstanding (Diluted) | 115 | 108 | 104 | 56 | 50 | 47 |
Shares Change (YoY) | 7.08% | 4.03% | 83.99% | 12.76% | 5.88% | 132.48% |
EPS (Basic) | -0.00 | -0.00 | -0.01 | -0.23 | -0.18 | -0.12 |
EPS (Diluted) | -0.00 | -0.00 | -0.01 | -0.23 | -0.18 | -0.12 |
Free Cash Flow | -0.14 | -0.09 | -0.76 | -0.67 | -2.26 | -4.13 |
Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.04 | -0.09 |
Gross Margin | - | - | - | - | - | -30.75% |
Operating Margin | - | - | - | - | - | -38806.68% |
Profit Margin | - | - | - | - | - | -80275.25% |
Free Cash Flow Margin | - | - | - | - | - | -58906.35% |
EBITDA | -0.15 | -0.16 | -0.58 | -1.34 | -2.34 | -2.72 |
D&A For EBITDA | 0.05 | 0.05 | 0.05 | 0.03 | 0.01 | 0 |
EBIT | -0.2 | -0.21 | -0.63 | -1.36 | -2.36 | -2.72 |